ArticleInfection and drug resistance2026
Comparison of Xpert MTB/RIF Assay and the Targeted Next-Generation Sequencing for the Diagnosis of Pleural Tuberculosis: A Prospective Comparative Diagnostic Accuracy Study.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the diagnostic performance of targeted next-generation sequencing (tNGS), a multiplex PCR-based and hybrid-capture sequencing platform targeting 198 respiratory pathogens, versus Xpert MTB/RIF in diagnosing pleural tuberculosis (TB) across diverse specimen types, given the limited sensitivity of existing assays in paucibacillary disease. Patients and Methods: Consecutive patients with suspected pleural TB were prospectively enrolled. Final diagnosis was established using a composite reference standard incorporating microbiological, histopathological, and clinical criteria. Paired sputum, pleural fluid, and pleural biopsy specimens underwent tNGS, Xpert MTB/RIF, and mycobacterial culture. Diagnostic performance metrics, including sensitivity and specificity, were calculated. A predefined paired comparison (n=105) between tNGS and Xpert MTB/RIF was performed, with agreement assessed using Cohen's kappa. Results: In the overall cohort (N = 142), tNGS demonstrated higher sensitivity than Xpert MTB/RIF and mycobacterial culture across specimen types when evaluated against the composite reference standard, while maintaining 100% specificity in the non-TB group (n = 8). In sputum samples, tNGS achieved a sensitivity of 72.73%, significantly outperforming Xpert MTB/RIF (21.43%) and MTB culture (16.30%). In pleural fluid, tNGS sensitivity (43.64%) exceeded that of Xpert MTB/RIF (30.49%) and MTB culture (24.14%), comparable to the performance of ADA ≥40 U/L (46.22%). The paired analysis confirmed that tNGS significantly outperformed Xpert MTB/RIF in overall diagnostic yield ( Conclusion: tNGS provides incremental diagnostic value over conventional molecular and culture-based assays in pleural tuberculosis, particularly in paucibacillary and culture-negative disease. It increases microbiological confirmation in culture- and Xpert-negative cases and is best positioned as a complementary second-line assay within a tiered diagnostic framework, despite no assessment of downstream clinical impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.